Sep 18, 2025
Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition
There are two FDA-approved medications for the metabolic disorder known as MASH. Roche is paying $2.4 billion to acquire 89bio and its late-stage MASH drug, giving the Swiss pharmaceutical giant the chance to bring a third medication and a different mechanism of action to this prevalent fatty liver disease. According to deal terms announced Thursday, Roche will pay $14.50 for all outstanding…
